Licensing · MENA · Announced 15 Sept 2025
Bio-Thera Solutions → Jamjoom Pharma
Licensing deal between Bio-Thera Solutions (China) and Jamjoom Pharma (Saudi Arabia), covering Secukinumab, announced 15 Sept 2025. Value: Undisclosed.
Parties: Bio-Thera Solutions, Ltd. (China) → JAMJOOM PHARMACEUTICALS CO. (Saudi Arabia)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- Middle East & North Africa (MENA)
- Therapeutic area
- Immunology / Inflammation
- Asset
- Secukinumab
- Announced
- 15 Sept 2025
Our analysis
Why this matters.
In September 2025, China's Bio-Thera granted Saudi Arabia's Jamjoom Pharma exclusive MENA rights to BAT2306, its proposed biosimilar to Novartis' Cosentyx (secukinumab) — one of the world's leading IL-17A inhibitors for plaque psoriasis and other inflammatory diseases.
The full analysis is free to read with a work email on this page.
Source: Pearce IP